Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

Stopped early · Phase 2

Conditions studied: Glioblastoma

In brief

The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.

Key facts

Study ID

NCT01898273

Run by

Cellectar Biosciences, Inc.

People needed

7

Starts

2014-02-01

Expected to finish

2015-12-01

Last updated by the study team

2015-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• newly diagnosed glioblastoma or recurrent/suspected recurrent glioblastoma
• scheduled to undergo a clinically-indicated surgery or biopsy (specific cohorts)
• ECOG performance status of 0 to 2 (Appendix C)
• 18 years of age or older
• has the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits
• has the ability to read, understand and provide written informed consent for the initiation of any study related procedures (or legal representative)
• if female of childbearing potential must have a negative pregnancy test within 24 hours of enrollment
• Women of childbearing potential and men who are able to father a child, must agree to use an effective method of contraception (e.g., oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Norplant, Depo-Provera) during the study and for 45 days following the last dose of the study drug.

You may not qualify if…

• ongoing grade 2 or greater toxicities due to previous therapies. However, tolerable grade 2 adverse (e.g. neuropathy) events may be allowed at the discretion of the investigator.
• has following laboratory abnormalities
• Platelets < 100,000/μL
• WBC < 3000/μL
• Hematocrit < 22%
• Serum creatinine > 2.5 mg/dL
• ALT > 1.5 x ULN
• Bilirubin > 1.5 x ULN
• ongoing chronic immunosuppressive therapy
• history of hypersensitivity to iodine
• any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise subject safety or interfere with the evaluation of the safety of the test drug
• women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial
• pregnancy or breast-feeding
• inability to comply with the protocol
• use of any investigational drug within 4 weeks of dosing (unless a longer time period is required by local regulations or the investigational agent)

Where it is running

• City of Hope — Duarte, California, United States
• Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• University of Maryland School of Medicine — Baltimore, Maryland, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Ohio State University Medical Center — Columbus, Ohio, United States
• Kettering Medical Center — Kettering, Ohio, United States
• Hospital of University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Wisconsin — Madison, Wisconsin, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.